Clinical Trials Using Personalized Synthetic Long Peptide Breast Cancer Vaccine

Clinical trials are research studies that involve people. The clinical trials on this list are studying Personalized Synthetic Long Peptide Breast Cancer Vaccine. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • Personalized Vaccine Therapy in Treating Patients with Triple-Negative Breast Cancer

    This phase I trial studies the side effects and best dose of personalized synthetic long peptide vaccine therapy in treating patients with triple-negative breast cancer. A peptide is a naturally occurring biological molecule made up of amino acids. The personalized synthetic long peptide vaccine is designed to target mutations (any change in the deoxyribonucleic acid [DNA] sequence of a cell) specific to each person’s tumor that are discovered during genetic testing of the tumor before study procedures start. Injection of this vaccine may be a way to generate an immune response to breast cancer cells.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri